医药制造业关系国计民生，是国家政策关注的重点，生物医药更是被列为“十二五”规划中的战略新兴产业。总体来看，医药制造业发展良好，各项指标都有大幅增长，但受国家限价政策调控和成本上升的压力，利润率却呈现下滑趋势。医药制造业凭借其刚性需求，有较强的抗风险能力，但行业集中度较低，业内兼并重组势在必行。
As the Pharmaceutical manufacturing Industry are directly related to benefits of the people's livelihood, the relevant national policy is at the focus of attention, with the biological medicine being classified as a "strategic emerging industry in the Twelfth Five Year Plan". Overall, the development of pharmaceutical manufacturing is good, the indicators have increased greatly. However, affected by the national price policy and the rising cost pressure, the profit margins are falling. Medicine manufacturing industry has resilient demand, strong ability to resist risks, but the industry concentration is low, mergers and acquisitions are imperative.
